[Skip to Navigation]
Sign In
Comment & Response
January 13, 2021

Neoadjuvant Chemotherapy in Pancreatic Cancer

Author Affiliations
  • 1Department of Medical Oncology, The Canberra Hospital, Garran, Australian Capital Territory, Australia
  • 2Australian National University Medical School, Australian National University, Canberra, Australian Capital Territory, Australia
  • 3Department of Surgery, The Canberra Hospital, Garran, Australian Capital Territory, Australia
JAMA Surg. 2021;156(4):396-397. doi:10.1001/jamasurg.2020.6276

To the Editor We congratulate Perri et al for publishing the comparative analysis of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic adenocarcinoma (PDAC).1

Perri et al have assessed the response rates by the modified Response Evaluation Criteria in Solid Tumours, version 1.1, and tumor volumetric analysis with a unique ellipsoid formula: Volume = π / (6 × L × W × H), where L indicates the longest axial diameter; W, shortest axial diameter; and H, craniocaudal diameter.

Add or change institution
×